Paroxetine Suspension
Product Images NDC 70954-319

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Paroxetine (NDC 70954-319). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This is a table with information about the fold change and 90% confidence interval for certain drugs and their interactions. The drugs listed are Pimozide, Desipramine, Propranolol, Digoxin, and Phenytoin. There are also some dosages listed, such as 2 mg for Pimozide and 100 mg for Desipramine. However, there isn't enough information to determine what the fold change and confidence interval measures are referring to. The last row may be a reference range.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
Not available.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This text seems to be a list of different parameters related to the population description for a study. It includes information about renal and hepatic impairment, age, dose, gender, Cmax and AUC. However, it is not clear what the actual study is about, what the purpose of each parameter is, or what the fold change and 90% CI refer to. Therefore, it is difficult to give a useful description based on this text alone.*
FDA Label Image

Paroxetine (Paroxetine Label)

Paroxetine (Paroxetine Label)
NDC 70954-319-10 250 mL PAROXETINE HCI ORAL SUSPENSION. Each 5 mL contains paroxetine hydrochloride equivalent to 10 mg paroxetine. Federal Law requires dispensing of Paroxetine HCI Oral Suspension with the Medication Guide provided with this bottle. See accompanying prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° o 86°F). Keep tightly closed. Shake well before using. Keep this and all medication out of the reach of children. Manufactured by Novitium Pharma LLC. Issued: 08/2021.*
FDA Label Image

Spl-table (Spl Table)

Spl-table (Spl Table)
This appears to be a table displaying the percentage of patients who experienced certain symptoms when treated with Paroxetine and Placebo for Generalized Anxiety Disorder or Posttraumatic Stress Disorder. The symptoms are grouped by body system or preferred term, with the percentage of patients who experienced the symptom under each treatment option. Some symptoms mentioned include headache, vasodilation, sweating, constipation, insomnia, and abnormal ejaculation, among others.*
FDA Label Image

Structure (Structure)

Structure (Structure)
FDA Label Image

Table-1 (Table 1)

Table-1 (Table 1)
The text appears to be the result of a table with rows and columns listing medication names and some associated symptoms. The medication listed is Paroxetine and the symptoms or side effects are listed in various categories like somnolence, insomnia, agitation, tremor, anxiety, dizziness, gastrointestinal, constipation, nausea, etc. The table displays various percentages and numbers associated with the severity level of each symptom and the medication dosage.*
FDA Label Image

Table-2 (Table 2)

Table-2 (Table 2)
This document appears to be a table listing the percentages of adverse reactions to Paroxetine and Placebo for 421 participants. It describes the effects on various body systems such as "Body as a Whole," "Cardiovascular," "Dermatologic," "Musculoskeletal," "Nervous System," "Respiration," "Special Senses," and "Genital/Urinary." The adverse reactions are listed in the table, with their corresponding percentages for both Paroxetine and Placebo. Some reactions indicated in this table include headache, asthenia, palpitation, sweating, nausea, dry mouth, dizziness, confusion, urinary frequency, and genital disorders.*
FDA Label Image

Table-3-2 (Table 3 2)

Table-3-2 (Table 3 2)
FDA Label Image

Table-3 (Table 3)

Table-3 (Table 3)
FDA Label Image

Table-5 (Table 5)

Table-5 (Table 5)
This appears to be a chart displaying the incidence of various symptoms experienced by patients taking different doses of the medication paroxetine. The symptoms are divided into categories based on body systems affected. The chart lists the percentages of patients who experienced each symptom within each dose group, as well as a placebo group. Symptoms include sweating, gastrointestinal issues, nervous system changes, special senses, and urogenital issues.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.